Filing Flows › Akebia Therapeutics (AKBA) › License, collaboration and other revenue revenue
Akebia Therapeutics (AKBA) License, collaboration and other revenue revenue by quarter
Akebia Therapeutics' License, collaboration and other revenue revenue was $2.1M in Q3 2026 (third quarter 2026), -12% from Q2 2026. Over the last 7 quarters it ranged from $1.5M (Q1 2025) to $3.3M (Q4 2025).
| Quarter | License, collaboration and other revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.1M | -12% | +5% |
| Q2 2026 | $2.4M | +52% | +18% |
| Q1 2026 | $1.6M | -53% | +0.5% |
| Q4 2025 | $3.3M | +68% | — |
| Q3 2025 | $2.0M | -2% | — |
| Q2 2025 | $2.0M | +30% | — |
| Q1 2025 | $1.5M | — | — |
Q3 2026 at a glance
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Akebia Therapeutics' License, collaboration and other revenue revenue?
Akebia Therapeutics' License, collaboration and other revenue revenue was $2.1M in Q3 2026 (third quarter 2026), -12% from Q2 2026.
How has Akebia Therapeutics' License, collaboration and other revenue revenue changed?
Over the last 7 quarters it ranged from $1.5M (Q1 2025) to $3.3M (Q4 2025).